Supporting Information

Duet of (–)-Epigallocatechin-3-Gallate and Doxorubicin Loaded by Polydopamine Coating ZIF-8 in Regulation of Autophagy for Chemo-Photothermal Synergistic Therapy

Xuerui Chen,^{1,3} Rongliang Tong,² Bingbing Liu,¹Hua Liu,² Xiaode Feng,² Shiping Ding,⁴ Qunfang Lei,¹ Guping Tang,¹ Jian Wu^{*},² Wenjun Fang^{*},¹

1. Department of Chemistry, Zhejiang University, Hangzhou 310027, China

2. Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.

3. Medical School of Shanghai University (in preparation), Shanghai University, Shanghai 200444, China.

4. The National Education Base for Basic Medical Sciences, Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310058, China.

Table of Contents

Experimental Details	S3
Synthesis of ZIF-8	S3
Synthesis of EGCG@ZIF-8	S3
Synthesis of EZP	S3
Intracellular ROS Quantification by Flow Cytometer	S4
Figures and Tables	S4
Table S1 IC50 and CI50 of different treatment	S4
Figure S1 TEM image and SEM image of ZIF-8	S5
Figure S2 TEM image, PXRD and DLS analysis of EGCG@ZIF-8 in pH 7.4	S5
Figure S3 DLS analysis of EGCG@ZIF-8 NPs in pH 5.0 and 6.0	S5
Figure S4 TEM images of EGCG@ZIF-8 in PBS of pH 5.0 and 6.0	S6
Figure S5 relationship between UV-Vis absorbance and EGCG concentration	S6
Figure S6 ROS levels of cells incubated with EGCG@ZIF-8	S7
Figure S7 Zn concentration of cells incubated with EGCG@ZIF-8	S7
Figure S8 Fluorescence emission spectra and UV/Vis spectra of EZP-FITC, EZ FITC	P and S7

Experimental Details

Synthesis of ZIF-8

0.20 g (0.66 mmol) of $Zn(NO_3)_2 \cdot 6H_2O$ was dissolved in 0.8 mL of methanol. Then, 10.00 mL of 2-methylimidazole (24.36 mmol) solution was added dropwise. They were stirred for 15 min. The product was collected by centrifugal separation and washed at least three times with mixture of alcohol and pure water. The powder products (ZIF-8 NPs) were dried at 51 °C under vacuum.

Synthesis of EGCG@ZIF-8

 $0.2 \text{ g} (0.66 \text{ mmol}) \text{ of } Zn(NO_3)_2 \cdot 6H_2O \text{ was dissolved in } 0.8 \text{ mL methanol. 4 mL of} EGCG stock solution (10 mg·mL⁻¹) was added into the <math>Zn(NO_3)_2$ solution under nitrogen atmosphere. After stirred for 5 min, 10 mL of 2-methylimidazole (24.36 mmol) solution was added dropwise. They were stirred for 15 min. The product was collected by centrifugal separation and washed at least three times with mixture of alcohol and pure water. The powder products (EGCG@ZIF-8 NPs) were dried at 51 °C under vacuum.

Synthesis of EZP

The synthesized EGCG@ZIF-8 was dispersed in a mixture solution of ethanol and the deionized water, then tetradecanol ethanol solution was put in the solution and stirred for 3 min. The EGCG@ZIF-8 was completely mixed in the solution of tetradecanol, and then EGCG@ZIF-8/ tetradecanol was synthesized. Because the tetradecanol has a hydrophilic head and a hydrophobic tail chain, which allows it to act as a surfactant and readily compatible with both hydrophilic and hydrophobic chemicals. In this case, $NH_3 \cdot H_2O$ was added to make it into an alkaline conditions, continued to add dopamine in the solution to form a shell for the EGCG@ZIF/PDA. Then followed by washing with deionized water several times, the precipitates were the product EGCG@ZIF/PDA nanocomposites which were denoted as EZP.

Intracellular ROS Quantification by flow cytometer and fluorescence microscope

Dichlorofluorescein-diacetate (DCFH-DA) was used as the fluorescent probe to detect the level of intracellular ROS. 1×10^{6} Hela cells were cultured in a six-well plate and were treated with EGCG, EGCG@ZIF-8 for 24 h, respectively. Cells were trypsinized and collected by centrifugal separation, then incubated with 10 mmol·L⁻¹ DCFH-DA for 15 min at 37 °C. Subsequently, cells were washed twice with PBS and analyzed by a flow cytometer. Meanwhile, the levels of intracellular ROS were also determined by a fluorescence microscope (Nikon, Japan).

Figures and Tables

Table S1 In vivo cytotoxicities and combination index (CI)^a of different treatment formulations against HeLa cells for 24 h incubation.

Formulations	$IC_{50}DOX/(\mu g \bullet mL^{-1})$	$IC_{50}EGCG/(\mu g \cdot mL^{-1})$	CI ₅₀
Free DOX	57.677		
Free EGCG		19.543	
EZPPD+NIR	3.5466	10.115	0.43977



Figure S1 (a) TEM image of ZIF-8 NPs; (b) SEM image of ZIF-8 NPs.



Figure S2 (a) TEM image of EGCG@ZIF-8 immersed in PBS (pH =7.4) for one month; (b) PXRD patterns of EGCG@ZIF-8 NPs and EGCG@ZIF-8 NPs immersed in PBS of pH 7.4 for 30 days; (c) Representative particle size distribution of EGCG@ZIF-8 NPs immersed in PBS of pH 7.4 for 30 days determined by DLS.



Figure S3 Representative particle size distribution of EGCG@ZIF-8 NPs in the PBS of pH 5.0 (a) and pH 6.0 (b) for 12 h determined by DLS.



Figure S4 TEM image of EGCG@ZIF-8 immersed in PBS of pH 5.0 (a) and pH 6.0 (b) for 12 h.



Figure S5 (a) The relationship between absorbance and EGCG concentration calculated by standard curve; (b) the UV-Vis spectra of EGCG@ZIF-8 NPs dissolved in 1 mol·L⁻¹ HCl and diluted by ultrapure water.



Figure S6 Intracellular ROS generation of HeLa cells incubated with EGCG@ZIF-8 NPs or EGCG for 12 h detected by flow cytometry and fluorescence microscope.



Figure S7 Cellular uptake of EGCG@ZIF-8 NPs. Zn concentration of cells incubated with EGCG@ZIF-8 NPs ($20 \ \mu g \cdot mL^{-1}$) and EGCG ($10 \ \mu g \cdot mL^{-1}$) for 24h.



Figure S8 (a) Fluorescence emission spectra of EZP-FITC, EZP and FITC at $\lambda ex=350$ nm; (b) The UV/Vis spectra of EZP-FITC, EZP and FITC.